Eversept Partners’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-243,800
Closed -$14.9M 88
2021
Q4
$14.9M Buy
+243,800
New +$16.9M 0.95% 29
2021
Q3
Sell
-199,000
Closed -$18.4M 107
2021
Q2
$18.4M Buy
+199,000
New +$16.9M 1.23% 25

Other funds holding ARKG

Eversept Partners's ARKG Position: Q2 2022 in Review

Eversept Partners sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 470,506 shares — an estimated $21.6M sold.

Eversept Partners first reported a position in ARKG in Q1 2021 and held it in 5 quarters. The position peaked at $71.6M in Q1 2021. 333 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

  • Eversept Partners reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
  • Eversept Partners sold 470,506 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $21.6M.
  • Eversept Partners first reported a position in ARK Genomic Revolution ETF in Q1 2021 and held it in 5 quarters.
  • Eversept Partners's ARK Genomic Revolution ETF position peaked at $71.6M in Q1 2021.
  • 333 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.